See the published version of this preprint at Cardio-Oncology.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
Short communication
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Hypertension impacts overall prognosis in cancer patients. There are no specific recommendations for its management in these patients. We report a case series of 5 cancer patients with suboptimal BP lowering and even worsening BP with ACEi or ARBs that improved to normal upon discontinuation of these drugs.
Keywords
Hypertension, Angiotensin-converting enzyme inhibitors, Angiotensin Receptor Blockers, Chemotherapeutic agents
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at Cardio-Oncology.
No community comments so far
Editorial decision: Accept
On 19 Aug, 2020
Editor assigned
On 29 Jul, 2020
Submission checks complete
On 28 Jul, 2020
Editor invited
On 28 Jul, 2020
Version 3
Posted 23 Jun, 2020
No comments provided
Editorial decision: Minor Revision
On 24 Jul, 2020
Editor assigned
On 21 Jun, 2020
Submission checks complete
On 20 Jun, 2020
Editor invited
On 20 Jun, 2020
No comments provided
Editorial decision: Minor Revision
On 11 Jun, 2020
Editor assigned
On 04 Jun, 2020
Submission checks complete
On 03 Jun, 2020
Editor invited
On 03 Jun, 2020
No comments provided
Editorial decision: Major Revision
On 06 May, 2020
Review #2 received
Received 20 Apr, 2020
Review #1 received
Received 14 Apr, 2020
Reviewers invited
Invitations sent on 09 Apr, 2020
Reviewer #1 agreed
On 09 Apr, 2020
Reviewer #2 agreed
On 09 Apr, 2020
Editor assigned
On 03 Apr, 2020
First submitted
On 02 Apr, 2020
Submission checks complete
On 02 Apr, 2020
Editor invited
On 02 Apr, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
See the published version of this preprint at Cardio-Oncology.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Short communication
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at Cardio-Oncology.
No community comments so far
Editorial decision: Accept
On 19 Aug, 2020
Editor assigned
On 29 Jul, 2020
Submission checks complete
On 28 Jul, 2020
Editor invited
On 28 Jul, 2020
Version 3
Posted 23 Jun, 2020
No comments provided
Editorial decision: Minor Revision
On 24 Jul, 2020
Editor assigned
On 21 Jun, 2020
Submission checks complete
On 20 Jun, 2020
Editor invited
On 20 Jun, 2020
No comments provided
Editorial decision: Minor Revision
On 11 Jun, 2020
Editor assigned
On 04 Jun, 2020
Submission checks complete
On 03 Jun, 2020
Editor invited
On 03 Jun, 2020
No comments provided
Editorial decision: Major Revision
On 06 May, 2020
Review #2 received
Received 20 Apr, 2020
Review #1 received
Received 14 Apr, 2020
Reviewers invited
Invitations sent on 09 Apr, 2020
Reviewer #1 agreed
On 09 Apr, 2020
Reviewer #2 agreed
On 09 Apr, 2020
Editor assigned
On 03 Apr, 2020
First submitted
On 02 Apr, 2020
Submission checks complete
On 02 Apr, 2020
Editor invited
On 02 Apr, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published article at Cardio-Oncology.
Hypertension impacts overall prognosis in cancer patients. There are no specific recommendations for its management in these patients. We report a case series of 5 cancer patients with suboptimal BP lowering and even worsening BP with ACEi or ARBs that improved to normal upon discontinuation of these drugs.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Loading...